

# AstraZeneca Allemansfond

The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca. For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab. The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).

## Performance

10.07.2025


YTD	1 week	1 mth.	3 mån	1 year	5 years	10 years
1.40%	1.39%	0.62%	10.50%	-3.54%	82.30%	223.09%

## Average performance

Average. perf.	2 years	3 years	5 years	10 years
Fund <sup>1</sup>	2.18%	8.86%	12.39%	12.49%
Index <sup>2</sup>	3.66%	8.62%	10.77%	-

<sup>1</sup> Calculated on the fund's monthly closing price  
<sup>2</sup> Benchmark index: SIX SRI Sweden Index GI (60%), AstraZeneca (40%). The information in the table refers to the benchmark index valid at any given time. In the event the fund has previously had other benchmark indexes, this information can be found in the fund's annual report.

## Five years performance



## Portfolio



### Portfolio manager comments — Q2 2025

Fund performance was negative during the second quarter.

The holdings with the most negative impact on fund returns were AstraZeneca, Hexagon and Essity. AstraZeneca underperformed due to concerns about tariffs and regulatory changes related to the healthcare sector in the US. Hexagon was negatively affected by its international exposure and sensitivity to the USD. Essity released a quarterly report that came in slightly below market expectations.

The strongest positive contributors were Autoliv, Sandvik and Beijer Ref, all of which delivered strong quarterly reports during the period.

## Fund manager



### Ulrika Orstadius

Experience in the fund industry 2011.  
Portfolio Manager since  
1 November 2022.

Main category	Equity Fund
Risk	4
Rate	3914.49 (10.07.2025)
Reporting Currency	SEK
Price/Trade	Daily
Total Rating™	★★★★
Minimum investment	0 SEK
Monthly savings	0 SEK
Traded on the Internet	No
Management Fee	0.9%
Entry charge	0%
Exit charge	0%
Fund assets	4,678 MSEK
Distribution per fund unit	-
Distribution date	-
Fund, date of launch	01.04.1984
Share class, date of launch	01.04.1984

## Largest holdings

AstraZeneca PLC	43.90%
Volvo AB Class B	6.06%
Sandvik AB	5.29%
Hexagon AB Class B	4.68%
Essity AB Class B	4.57%
Beijer Ref AB Class B	4.08%
Skandinaviska Enskilda Banken AB Class A	3.77%
Autoliv Inc SEDR	3.34%
Epiroc AB Ordinary Shares - Class A	3.06%
Sweco AB Class B	2.87%

Autoliv exceeded market expectations with results that demonstrated solid resilience. Sandvik also reported stable figures, which were well received in an otherwise uncertain market climate. Beijer Ref delivered a report above expectations and emphasized that the company had not seen any major negative impact from tariff concerns.

During the period, the fund added a new holding in Systemair, a global supplier of ventilation equipment that stands to benefit from a potential improvement in sentiment around the European construction market and energy efficiency in buildings. The fund also increased its holding in AstraZeneca to maintain a significant allocation after the share price declined, and reduced its holding in Assa Abloy due to its relatively high exposure to the US housing market.

We continue to focus on investee companies with sustainable business models and competitive offerings that support resilient and profitable growth.

As of: 09.07.2025

---

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. [Summary of investors' rights](#).

The fund's fact sheet, risk level, fund rules and prospectus are available at [www.handelsbanken.se/funds](http://www.handelsbanken.se/funds). Handelsbanken does not assume liability for any errors in the information.

[www.handelsbanken.se/funds](http://www.handelsbanken.se/funds)

**Handelsbanken**